Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin

Thrombosis and Haemostasis

Volumn 80, Issue 6, 1998, Pages 936-941

  Rauch, Joyce ^a   Tannenbaum, Marion ^a   Neville, Carolyn ^a   Fortin, Paul R ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G ANTIBODY; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PLASMA PROTEIN; PROTHROMBIN;

ADULT; AGED; ARTICLE; BILAYER MEMBRANE; CLINICAL ARTICLE; FEMALE; HUMAN; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031790361     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615392     Document Type: Article

References (33)

1. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" antibodies. Blood 1994; 84: 2854-67.
2. Rauch J, Janoff AS. Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Lupus 1996: 5: 498-502.
3. Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thromb Diath Haemorrh 1959; 3: 237-56.
4. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA.Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
5. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25.
6. Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-16.
7. Fleck RA, Rapaport SI, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9.
8. 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-92.
9. Rao LVM, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-82.
10. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997; 77: 486-91.
11. Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892-6.
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
13. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996; 88: 1873-80.
14. Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986; 261: 9672-7.
15. 2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-8.
16. Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80: 16-22.
17. 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
18. Wu JR, Lentz BR. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes. Thromb Haemost 1994; 71: 596-604.
19. Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by "antiphospholipid antibodies": possible modes of action. Lupus 1994; 3: 223-8.
20. Zwaal RFA. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515: 163-205.
21. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
22. van Rijn JLML, Govers-Riemslag JWP, Zwaal RFA, Rosing J. Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry 1984; 23: 4557-64.
23. Jones ME, Lentz BR, Dombrose FA, Sanberg H. Comparison of the abilities of synthetic and platelet-derived membranes to enhance thrombin formation. Thromb Res 1985; 39: 711-24.
24. Papahadjopoulos D, Hanahan DJ. Observation on the interaction of phospholipids and certain clotting factors in prothrombin activator formation. Biochem Biophys Acta 1964; 90: 436-9.
25. Esmon CT, Owen WG, Jackson CM. The conversion of prothrombin to thrombin: V. The activation of prothrombin by factor Xa in the presence of phospholipid. J Biol Chem 1974; 249: 7798-807.
26. Gerads I, Govers-Riemslag JWP, Tans G, Zwaal RFA, Rosing J. Prothrombin activation on membranes with anionic lipids containing phosphate, sulfate, and/or carboxyl groups. Biochemistry 1990: 29: 7967-74.
27. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
28. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
29. Karmochkine M, Cacoub P, Piette JC, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992; 10: 603-5.
30. Staub HL, Harris EN, Khamashta MA, Savidge G, Chahade WH, Hughes GRV. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989; 48: 166-9.
31. Karmochkine M, Berard M, Piette JC, Cacoub P, Aillaud MF, Harlé JR, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993; 2: 157-60.
32. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-9.
33. Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-60.